

## ***MolMed: Publication of the Minutes of the Ordinary Shareholders Meeting held on April 30<sup>th</sup> 2019.***

Milan (Italy), May 15<sup>th</sup> 2019 – MolMed S.p.A. (MLMD.MI) (the “Company”), a biotechnology company focused on research, development, production and clinical validation of gene and cell therapies for the treatment of cancer and rare diseases, informs that the Minutes of the Ordinary Shareholders Meeting held on April 30<sup>th</sup> 2019 is available (in Italian) to the public at the Company registered office, on the Company website ([www.molmed.com](http://www.molmed.com)) in the page dedicated to the Shareholders Meeting held on April 30<sup>th</sup> 2019 - section Investors/Shareholder Information/Shareholders Meeting - and on the authorized storage device 1Info-Storage ([www.1info.it](http://www.1info.it)).

### ***About MolMed***

MolMed S.p.A. is a clinical stage biotech company focused on research, development, manufacturing and clinical validation of innovative therapies. MolMed's product portfolio includes proprietary anti-tumor therapies in both clinical and preclinical development: Zalmoxis® (TK) is a cell therapy based on donor T cells genetically engineered to enable bone marrow transplants from partially compatible donors for patients with high-risk hematological malignancies, eliminating post-transplant immunosuppression prophylaxis and inducing a rapid immune reconstitution. Zalmoxis®, that received orphan drug designation and is currently in Phase III in a high-risk population of acute leukemia patients, but has already obtained a Conditional Marketing Authorization by the European Commission in the second half of 2016 as well as reimbursement conditions in Italy and in Germany at the beginning of 2018. Still focusing on this cell & gene technology, the Company is developing a new therapeutic platform based on Chimeric Antigen Receptor (CAR), both autologous and allogeneic; the most advanced product, CAR-T CD44v6, which in March 2019 received the authorization to start human clinical trials in onco-hematologic indications (AML and MM), following an extensive pre-clinical phase; the product is potentially effective also in several epithelial solid tumors. With regards to allogeneic CARs, MolMed is developing a pipeline based on NK (Natural Killer) cells, following a research agreement signed in 2018 with Glycostem. MolMed is also the first company in Europe to have obtained the GMP manufacturing authorization for cell & gene therapies for its proprietary products (Zalmoxis®) as well as for third parties and/or in partnership (Strimvelis, an Orchard gene therapy for the ADA-SCID). With reference to GMP development and manufacturing activities for third parties, MolMed signed numerous partnership agreements with leading European and US companies. In the field of innovative oncological therapies MolMed pipeline also includes NGR-hTFN, a therapeutic agent for the treatment of solid tumors. MolMed, founded in 1996 as an academic spin-off of the San Raffaele Scientific Institute, is listed on the main market (MTA) of the Milan stock exchange managed by Borsa Italiana since March 2008. MolMed is headquartered and based in Milan, at the San Raffaele Biotechnology Department (DIBIT) and has an operating unit at OpenZone in Bresso.

### ***For further information:***

**Ilaria Candotti**  
***Investor Relations & Communication Manager***  
MolMed S.p.A.  
+39 02 21277.205  
[investor.relations@molmed.com](mailto:investor.relations@molmed.com)

**Tommasina Cazzato**  
***Press Office***  
Community Group  
+39 345 7357751  
[tommasina.cazzato@communitygroup.it](mailto:tommasina.cazzato@communitygroup.it)

